iTeos Therapeutics
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors (NCT06547957) | iTeos Therapeutics | 2023-07-07 |
| Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer (NCT05403385) | iTeos Therapeutics | 2022-08-26 |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (NCT05289492) | iTeos Therapeutics | 2022-05-01 |
| New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer (NCT05117177) | iTeos Therapeutics | 2021-07-01 |
| First-In-Human Study of EOS884448 in Participants with Advanced Cancers. (NCT04335253) | iTeos Therapeutics | 2020-02-18 |
| First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer (NCT03873883) | iTeos Therapeutics | 2019-02-05 |
Track iTeos Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.